Munich Startup
Insecta

Insecta

Insecta is the world’s first insect-based chitin and chitosan production startup for pharmaceutical and research, which tend to maintain superior quality and year-round availability. Unlike traditional sources like shrimp or...

Founded2026
Business ModelB2B
IndustryBioTech
This content was machine translated.

About Insecta

Insecta is the world’s first insect-based chitin and chitosan production startup for pharmaceutical and research, which tend to maintain superior quality and year-round availability. Unlike traditional sources like shrimp or crabs which is leading to ecological degradation, insects provide a sustainable and scalable supply of chitin and chitosan without depending on marine resources. Cost of extraction from insects is way cheaper than extracting from sea source. Insects are easy to rare, have short life cycle with very high reproduction rate. Insect’s exoskeleton contains 30-50% of chitin, double compared to the sea source. The market for chitosan is currently at 15.72 billion USD and estimated to reach 96 billion USD by 2033 with a CAGR of 22.32%. The total available market is at 60,000 tonnes whereas current production is at 27,000 tonnes. Chitosan has numerous applications across various industries and is an important raw material. Chitosan is used in water purification, pharmaceuticals, textile industry, cosmetics, and to produce biodegradable plastic, food packaging, chitosan films to extend the shelf life of fruits and vegetables, contributing to both waste reduction and sustainability goals.

More like this

Discover relevant articles, startups, and events from the ecosystem

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

B2BBioTech

2026Founded
-Team size
Seed stage

ProviGenAI

ProviGenAI develops a software platform for automated experiments and data-driven process optimization. Many laboratories and biotechnology development environments already have extensive automation in place, yet the planning, evaluation, and adaptation of experiments continues to be done manually. Our platform combines automated laboratory workflows with AI-based optimization. It translates experimental protocols into executable workflows, orchestrates experiments on existing automation systems, and analyzes the resulting data to continuously improve parameters. This creates closed learning loops between experiment, analysis, and decision-making. Teams can optimize biotechnological processes—such as fermentation, screening, or bioprocess development—significantly faster and more efficiently.

B2BBioTech

2026Founded
-Team size
Seed stage